301 related articles for article (PubMed ID: 36102111)
1. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
[TBL] [Abstract][Full Text] [Related]
2. Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
Pouliot F; Rouleau M; Neveu B; Toren P; Morin F; Vélot L; Ding K; Caron P; Lacombe L; Lévesque É; Klotz L; Guillemette C
J Urol; 2020 May; 203(5):940-948. PubMed ID: 31845837
[TBL] [Abstract][Full Text] [Related]
3. Preliminary observations on steroid metabolism in isolated epithelum of guinea pig seminal vesicle.
Steer RC; Veneziale CM
Andrologia; 1977; 9(2):141-54. PubMed ID: 142430
[TBL] [Abstract][Full Text] [Related]
4. The 11β-hydroxyandrostenedione pathway and C11-oxy C
du Toit T; Swart AC
J Steroid Biochem Mol Biol; 2020 Feb; 196():105497. PubMed ID: 31626910
[TBL] [Abstract][Full Text] [Related]
5. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
6. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.
Ming DS; Pham S; Deb S; Chin MY; Kharmate G; Adomat H; Beheshti EH; Locke J; Guns ET
J Steroid Biochem Mol Biol; 2014 Sep; 143():19-28. PubMed ID: 24565566
[TBL] [Abstract][Full Text] [Related]
7. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
Labrie F; Bélanger A; Cusan L; Candas B
J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
[TBL] [Abstract][Full Text] [Related]
8. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.
Tamae D; Byrns M; Marck B; Mostaghel EA; Nelson PS; Lange P; Lin D; Taplin ME; Balk S; Ellis W; True L; Vessella R; Montgomery B; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2013 Nov; 138():281-9. PubMed ID: 23851165
[TBL] [Abstract][Full Text] [Related]
9. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
10. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
[TBL] [Abstract][Full Text] [Related]
12. Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.
Zang T; Taplin ME; Tamae D; Xie W; Mesaros C; Zhang Z; Bubley G; Montgomery B; Balk SP; Mostaghel EA; Blair IA; Penning TM
Endocr Relat Cancer; 2017 Aug; 24(8):393-404. PubMed ID: 28663228
[TBL] [Abstract][Full Text] [Related]
13. Basis for hormonal management of advanced prostate cancer.
Geller J
Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.
Zang T; Tamae D; Mesaros C; Wang Q; Huang M; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):342-355. PubMed ID: 27531846
[TBL] [Abstract][Full Text] [Related]
15. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
17. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.
Sharifi N
J Investig Med; 2012 Feb; 60(2):504-7. PubMed ID: 22064602
[TBL] [Abstract][Full Text] [Related]
18. Effect of castration monotherapy on the levels of adrenal androgens in cancerous prostatic tissues.
Arai S; Miyashiro Y; Shibata Y; Tomaru Y; Kobayashi M; Honma S; Suzuki K
Steroids; 2011 Feb; 76(3):301-8. PubMed ID: 21147140
[TBL] [Abstract][Full Text] [Related]
19. Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro.
Pham S; Deb S; Ming DS; Adomat H; Hosseini-Beheshti E; Zoubeidi A; Gleave M; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():436-44. PubMed ID: 25201454
[TBL] [Abstract][Full Text] [Related]
20. LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide.
van Nuland M; Venekamp N; Wouters WME; van Rossum HH; Rosing H; Beijnen JH
J Pharm Biomed Anal; 2019 Jun; 170():161-168. PubMed ID: 30925273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
